UBS Group
ZBIO

UBS Group’s Zenas BioPharma ZBIO Stock Holding History

UBS Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18M Buy
367,405
+297,910
+429% +$6.69M ﹤0.01% 3697
2025
Q4 		$2.52M Buy
69,495
+34,003
+96% +$1.12M ﹤0.01% 4740
2025
Q3 		$788K Buy
35,492
+11,229
+46% +$183K ﹤0.01% 5751
2025
Q2 		$235K Buy
24,263
+3,498
+17% +$34.1K ﹤0.01% 6611
2025
Q1 		$164K Sell
20,765
-110,900
-84% -$868K ﹤0.01% 6677
2024
Q4 		$1.08M Buy
131,665
+131,606
+223,061% +$2.05M ﹤0.01% 5246
2024
Q3 		$998 Buy
+59
New +$1.06K ﹤0.01% 8753

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

UBS Group's ZBIO Position: Q1 2026 in Review

UBS Group increased its Zenas BioPharma (ZBIO) stake by 429% in Q1 2026, buying an estimated $6.69M and bringing the position to 367,405 shares worth $7.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3697.

UBS Group first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • UBS Group held 367,405 shares of Zenas BioPharma worth $7.18M as of Q1 2026.
  • UBS Group bought 297,910 Zenas BioPharma shares in Q1 2026, an estimated $6.69M.
  • Zenas BioPharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3697 holding.
  • UBS Group first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.